Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

Core Viewpoint - Serina Therapeutics, Inc. is facing potential delisting from the NYSE due to insufficient stockholders' equity and losses in recent fiscal years, necessitating a compliance plan to regain listing standards by July 2027 [1][2]. Company Overview - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases, utilizing its proprietary POZ Platform for drug optimization [3]. - The company is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [3]. POZ Platform Technology - The POZ technology is based on a synthetic polymer that enhances drug delivery by improving control over drug loading and release rates [4]. - This technology aims to address limitations of existing drugs, such as toxicity and short half-life, by maintaining stable blood levels of therapeutic agents [4]. SER-252 Development - SER-252 is an investigational therapy designed to provide continuous dopaminergic stimulation for Parkinson's disease, potentially reducing motor complications associated with traditional treatments [6]. - Preclinical studies indicate that SER-252 may offer therapeutic benefits without causing skin reactions [6]. Compliance and Listing Status - The company must submit a plan by February 8, 2026, detailing actions to regain compliance with NYSE listing standards by July 9, 2027 [2]. - If the compliance plan is accepted, Serina will remain listed during the "Cure Period" and will undergo periodic reviews [2].